Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant MYD88 and wildtype CD79

Documenti analoghi

• Dramatic Response with Single-Agent Ibrutinib in Multiply Relapsed Marginal Zone Lymphoma with MYD88(L265P) Mutation
  di: Lynch, Ryan C., et al.
  Pubblicazione: (2017)
• CD79B and MYD88 Mutations in Splenic Marginal Zone Lymphoma
  di: Trøen, Gunhild, et al.
  Pubblicazione: (2013)
• Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations
  di: Kersten, M J, et al.
  Pubblicazione: (2014)
• Lack of Durable Remission with Conventional-Dose Total Skin Electron Therapy for the Management of Sezary Syndrome and Multiply Relapsed Mycosis Fungoides
  di: Campbell, Belinda A., et al.
  Pubblicazione: (2019)
• Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice
  di: Visco, Carlo, et al.
  Pubblicazione: (2020)